For example, the detection of FLT3-ITD mutations in AML cells may predict their response to venetoclax, and combining the FLT3 inhibitor quizartinib (106) or gilteritinib (32, 107) with venetoclax may result in a better therapeutic effect. The gene discussed is FLT3; the disease is acute myeloid leukemia.